Loading...
Market
Percentage change in Rite Aid's stock price one month after ruling
2
Resolution / Starting Odds
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Stock market data from financial information services such as Yahoo Finance or Bloomberg
Story
Rite Aid Wins $200 Million Dispute Over Elixir Sale After Judge's Monday Ruling
Jun 24, 2024, 06:00 PM
Rite Aid has successfully defeated MedImpact Healthcare Systems in a $200 million dispute over the sale of its pharmacy benefit manager, Elixir. A judge ruled on Monday that MedImpact is not entitled to recoup the $200 million in extra costs, as it assumed Elixir's debts when it acquired the company. This ruling absolves Rite Aid of any responsibility for the additional costs tied to the recent acquisition.
View original story
Similar markets
Increase by > 5% • 25%
Increase by ≤ 5% • 25%
Decrease by ≤ 5% • 25%
Decrease by > 5% • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Increase > 5% • 25%
Decrease > 5% • 25%
No change • 25%
Other • 25%
Increase by over 5% • 25%
Increase by 0-5% • 25%
Decrease by 0-5% • 25%
Decrease by over 5% • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Increase by more than 10% • 25%
Decrease by more than 10% • 25%
No significant change (within ±10%) • 25%
Other • 25%
Yes • 50%
No • 50%
Increase over 10% • 25%
Decrease over 10% • 25%
No significant change • 25%
Other • 25%
Increase by over 10% • 25%
Decrease by over 10% • 25%
Change within +/- 10% • 25%
No significant change • 25%
Below $10 • 25%
$10 - $15 • 25%
$15 - $20 • 25%
Above $20 • 25%
Stock price increases by over 10% • 25%
Stock price decreases by over 10% • 25%
Stock price remains within 10% range • 25%
Stock is delisted • 25%